FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010286218> ?p ?o ?g. }

• W2010286218 endingPage "408" @default.
• W2010286218 startingPage "402" @default.
• W2010286218 abstract "Radiochemotherapy (RCT) is an effective treatment for locally advanced non-small-cell lung cancer (NSCLC), but can be limited by acute and late toxicities (esophagitis, pneumonitis, and myelosuppression). This trial investigated whether pretreatment with amifostine, a radioprotector, could reduce the incidence of radiochemotherapy-induced acute and late toxicities.Between October 1997 and August 1999, 73 patients with previously untreated Stage IIIa-IIIb NSCLC were randomized to treatment with RCT alone (n = 36) or RCT plus amifostine (300 mg/m(2) daily i.v. infusion, n = 37). RCT consisted of either paclitaxel (60 mg/m(2)) or carboplatin (AUC 2) once weekly during a 5- to 6-week course of conventional radiotherapy given as 2 Gy/5 days/week to a total dose of 55 to 60 Gy. Blood cell counts were measured weekly; esophagitis and acute lung toxicity were evaluated during the treatment course. Treatment efficacy was assessed following World Health Organization criteria for response. Late lung toxicity was assessed at 3 and 6 months after RCT and was graded from 0 to 4 according to the Radiation Therapy Oncology Group/European Organization for the Research and Treatment of Cancer criteria.A total of 68 patients were evaluable for toxicity analysis (RCT group, n = 32; RCT + amifostine, n = 36). There was no significant difference between treatment arms in patient baseline characteristics. The incidence of Grade >or=3 esophagitis during RCT was significantly lower for patients receiving amifostine than for patients receiving RCT alone (38.9% vs. 84.4%%, p < 0.001). Furthermore, the incidence of Grade >or=3 acute pulmonary toxicity was significantly reduced in patients treated with RCT plus amifostine compared to patients who received RCT alone (19.4% vs. 56.3%, p = 0.002). At 3 months after RCT, patients treated with amifostine had a significantly lower incidence of pneumonitis than patients who received RCT alone (p = 0.009). Combined response rates (complete plus partial responses) were 82.2% in the RCT group and 88.8% in the RCT plus amifostine group (p = 0.498). Amifostine is effective in reducing the incidence of both acute and late toxicities associated with RCT in patients with locally advanced NSCLC without compromising antitumor efficacy." @default.
• W2010286218 created "2016-06-24" @default.
• W2010286218 creator A5043331249 @default.
• W2010286218 creator A5060082784 @default.
• W2010286218 creator A5063094755 @default.
• W2010286218 creator A5070298773 @default.
• W2010286218 creator A5077195933 @default.
• W2010286218 creator A5089524269 @default.
• W2010286218 date "2003-10-01" @default.
• W2010286218 modified "2023-10-10" @default.
• W2010286218 title "Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non–small-cell lung cancer" @default.
• W2010286218 cites W1831241863 @default.
• W2010286218 cites W1855747096 @default.
• W2010286218 cites W1863042099 @default.
• W2010286218 cites W1870576657 @default.
• W2010286218 cites W1930978022 @default.
• W2010286218 cites W1944220675 @default.
• W2010286218 cites W1955985599 @default.
• W2010286218 cites W1965920084 @default.
• W2010286218 cites W1968969593 @default.
• W2010286218 cites W2008315798 @default.
• W2010286218 cites W2009650722 @default.
• W2010286218 cites W2057157978 @default.
• W2010286218 cites W2065057508 @default.
• W2010286218 cites W2072198722 @default.
• W2010286218 cites W2076880391 @default.
• W2010286218 cites W2091053660 @default.
• W2010286218 cites W2095122167 @default.
• W2010286218 cites W2105934027 @default.
• W2010286218 cites W2138178697 @default.
• W2010286218 cites W2140641839 @default.
• W2010286218 cites W2155053061 @default.
• W2010286218 cites W2161495797 @default.
• W2010286218 cites W2188879726 @default.
• W2010286218 cites W2257430737 @default.
• W2010286218 cites W2326792610 @default.
• W2010286218 cites W4237288361 @default.
• W2010286218 cites W4239676301 @default.
• W2010286218 cites W4239714259 @default.
• W2010286218 cites W4251309185 @default.
• W2010286218 doi "https://doi.org/10.1016/s0360-3016(03)00590-x" @default.
• W2010286218 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12957251" @default.
• W2010286218 hasPublicationYear "2003" @default.
• W2010286218 type Work @default.
• W2010286218 sameAs 2010286218 @default.
• W2010286218 citedByCount "83" @default.
• W2010286218 countsByYear W20102862182012 @default.
• W2010286218 countsByYear W20102862182013 @default.
• W2010286218 countsByYear W20102862182014 @default.
• W2010286218 countsByYear W20102862182015 @default.
• W2010286218 countsByYear W20102862182016 @default.
• W2010286218 countsByYear W20102862182017 @default.
• W2010286218 countsByYear W20102862182018 @default.
• W2010286218 countsByYear W20102862182019 @default.
• W2010286218 countsByYear W20102862182020 @default.
• W2010286218 countsByYear W20102862182021 @default.
• W2010286218 countsByYear W20102862182022 @default.
• W2010286218 crossrefType "journal-article" @default.
• W2010286218 hasAuthorship W2010286218A5043331249 @default.
• W2010286218 hasAuthorship W2010286218A5060082784 @default.
• W2010286218 hasAuthorship W2010286218A5063094755 @default.
• W2010286218 hasAuthorship W2010286218A5070298773 @default.
• W2010286218 hasAuthorship W2010286218A5077195933 @default.
• W2010286218 hasAuthorship W2010286218A5089524269 @default.
• W2010286218 hasBestOaLocation W20102862181 @default.
• W2010286218 hasConcept C126322002 @default.
• W2010286218 hasConcept C141071460 @default.
• W2010286218 hasConcept C143998085 @default.
• W2010286218 hasConcept C168563851 @default.
• W2010286218 hasConcept C2776256026 @default.
• W2010286218 hasConcept C2776694085 @default.
• W2010286218 hasConcept C2777714996 @default.
• W2010286218 hasConcept C2778239845 @default.
• W2010286218 hasConcept C2779134260 @default.
• W2010286218 hasConcept C2779387952 @default.
• W2010286218 hasConcept C2779524853 @default.
• W2010286218 hasConcept C2779920096 @default.
• W2010286218 hasConcept C2781451048 @default.
• W2010286218 hasConcept C29730261 @default.
• W2010286218 hasConcept C43270747 @default.
• W2010286218 hasConcept C509974204 @default.
• W2010286218 hasConcept C71924100 @default.
• W2010286218 hasConcept C90924648 @default.
• W2010286218 hasConceptScore W2010286218C126322002 @default.
• W2010286218 hasConceptScore W2010286218C141071460 @default.
• W2010286218 hasConceptScore W2010286218C143998085 @default.
• W2010286218 hasConceptScore W2010286218C168563851 @default.
• W2010286218 hasConceptScore W2010286218C2776256026 @default.
• W2010286218 hasConceptScore W2010286218C2776694085 @default.
• W2010286218 hasConceptScore W2010286218C2777714996 @default.
• W2010286218 hasConceptScore W2010286218C2778239845 @default.
• W2010286218 hasConceptScore W2010286218C2779134260 @default.
• W2010286218 hasConceptScore W2010286218C2779387952 @default.
• W2010286218 hasConceptScore W2010286218C2779524853 @default.
• W2010286218 hasConceptScore W2010286218C2779920096 @default.
• W2010286218 hasConceptScore W2010286218C2781451048 @default.
• W2010286218 hasConceptScore W2010286218C29730261 @default.
• W2010286218 hasConceptScore W2010286218C43270747 @default.

• next